Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost ...

Lupus nephritis (LN) is a condition in which systemic lupus erythematosus (SLE) affects the kidney, causing inflammation and damage. Renal disease develops early in SLE, with up to two-thirds of ...

New Method Predicts Worsening of Chronic Kidney Disease Sep. 12, 2024 — Researchers have developed a new method that could be a significant step in the treatment of chronic kidney disease.

Preconception predictors of adverse pregnancy outcomes among women with SLE include previous lupus nephritis, chronic hypertension, SLE disease activity, and APS.

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the U.S. Food and ...

A four-year-old boy in Kurnool was diagnosed with Lipoprotein Glomerulopathy, a rare kidney disease, marking the first case ...

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Kezar Life Sciences’ zetomipzomib, an ...

Kezar Life Sciences Inc. (NASDAQ:KZR) announced that it was informed via teleconference with the FDA that the zetomipzomib ...

The FDA has placed Kezar Life Sciences’ lupus trial on hold after the biotech flagged four deaths during the phase 2b study.

The US FDA has imposed a clinical hold on Kezar Life Sciences’ IND application for zetomipzomib, aimed at treating lupus ...

Panelists discuss the updated treatment recommendations for lupus nephritis in the Kidney Disease Improving Global Outcomes and European Alliance of Associations for Rheumatology guidelines ...